Kangstem Biotech has been growing earnings at an average annual rate of 13.3%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been declining at an average rate of 11% per year.
How Kangstem Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
KOSDAQ:A217730 Revenue, expenses and earnings (KRW Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
3,423
-10,140
5,681
12,296
31 Dec 25
3,572
-10,482
5,822
12,577
31 Dec 24
7,746
-6,762
6,990
12,143
30 Sep 24
12,775
-10,089
8,908
12,380
30 Jun 24
13,278
-10,925
9,421
13,158
31 Mar 24
12,160
-20,640
9,605
12,932
31 Dec 23
12,704
-21,949
10,272
14,030
30 Sep 23
9,807
-19,299
9,277
14,185
30 Jun 23
11,835
-19,883
9,810
14,259
31 Mar 23
14,620
-19,800
10,381
14,133
31 Dec 22
16,301
-20,236
11,076
14,220
30 Sep 22
15,423
-22,709
12,824
15,189
30 Jun 22
15,948
-21,950
12,296
15,025
31 Mar 22
14,614
-21,338
11,861
15,049
31 Dec 21
12,405
-21,348
10,636
14,653
30 Sep 21
10,712
-18,841
7,671
13,206
30 Jun 21
8,577
-17,479
7,273
12,512
31 Mar 21
9,101
-16,172
7,094
12,646
31 Dec 20
9,138
-18,471
6,799
12,639
30 Sep 20
8,608
-23,751
8,142
13,421
30 Jun 20
8,026
-24,886
8,462
13,661
31 Mar 20
6,475
-27,651
9,587
13,066
31 Dec 19
6,005
-24,635
9,994
12,415
30 Sep 19
5,997
-18,973
8,830
10,639
30 Jun 19
8,572
-17,123
8,524
9,035
31 Mar 19
8,874
-15,332
6,891
7,436
31 Dec 18
9,165
-13,648
6,406
6,181
30 Sep 18
8,411
-13,773
4,451
5,466
30 Jun 18
7,276
-15,699
5,813
6,200
31 Mar 18
9,156
-15,141
7,994
6,475
31 Dec 17
9,133
-15,423
8,060
6,715
30 Sep 17
7,587
-12,323
9,241
6,663
30 Jun 17
5,122
-10,089
7,140
5,871
31 Dec 16
843
-8,300
4,246
5,529
Quality Earnings: A217730 is currently unprofitable.
Growing Profit Margin: A217730 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A217730 is unprofitable, but has reduced losses over the past 5 years at a rate of 13.3% per year.
Accelerating Growth: Unable to compare A217730's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A217730 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.6%).
Return on Equity
High ROE: A217730 has a negative Return on Equity (-16.27%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/08/08 15:08
End of Day Share Price
2026/08/07 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kangstem Biotech Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.